156353-01-4

Basic information

• Product Name: N-Methoxy-N-Methyltetrahydropyran-4-carboxaMide
• Synonyms: N-Methoxy-N-Methyltetrahydropyran-4-carboxaMide;Tetrahydro-pyran-4-carboxylic acid methoxy-methyl-amide;N-methoxy-N-methyloxane-4-carboxamide
• CAS NO: 156353-01-4
• Molecular Formula: C₈H₁₅NO₃
• Molecular Weight: 173.2096
• Mol File: 156353-01-4.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 234.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.090±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-Methoxy-N-Methyltetrahydropyran-4-carboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-Methoxy-N-Methyltetrahydropyran-4-carboxaMide(156353-01-4)
• EPA Substance Registry System: N-Methoxy-N-Methyltetrahydropyran-4-carboxaMide(156353-01-4)

Safety Data

• Hazardous Substances Data: 156353-01-4(Hazardous Substances Data)

Usage

General Description

N-Methoxy-N-Methyltetrahydropyran-4-carboxamide is an organic chemical compound that belongs to the class of organic compounds known as tetrahydropyrans, which are compounds containing a perhydropyran ring, a six-membered heterocyle with five carbon and one oxygen atom, and a carboxamide group (-CONH2). The detailed characteristics, properties, and reactivity of this compound may vary accordingly to its specific molecular structure. As its chemical properties and applications are not widely known or documented, it might be of interest to researchers in organic chemistry or in the chemical industry in general. Further laboratory studies will be required to determine its potential uses, risks and safety measures.

Upstream product

• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 137052-08-5 1-(tetrahydro-2H-pyran-4-yl)ethan-1-one 
• 1295521-50-4 4-(1-(2-pyrrolidin-1-yl-ethyl)-4-(tetrahydro-pyran-4-yl)-1H-imidazol-2-yl)-piperidine 
• 1334712-17-2 3-(oxan-4-yl)-1-phenyl-1H-pyrazolo[3,4-c]pyridine 
• 1427555-68-7 1-[4-(fluoromethyl)phenyl]-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine 

Relevant articles and documents

Non-substrate based, small molecule inhibitors of the human isoprenylcysteine carboxyl methyltransferase

Activating mutations of human K-Ras proteins are among the most common oncogenic mutations, present in approximately 30% of all human cancers. Posttranslational modifications to K-Ras guide it to the plasma membrane and disruption of this localization inhibits the growth of Ras-driven cancers. The human isoprenylcysteine carboxyl methyltransferase (hIcmt) enzyme catalyzes the final α-carboxyl methylesterification of the C-terminal farnesyl cysteine of K-Ras, which is necessary for its proper localization. Thus, hIcmt inhibition is a regarded as a promising cancer therapy. A high quality inhibitor of hIcmt with in vivo activity would advance hIcmt research and drug development. Herein, Wwe report the results of a screen for small molecule hIcmt inhibitors in a library of molecules that were not hIcmt substrate analogs. The lead compound identified by this screen (1) was modified to remove chemical liabilities and to increase potency. The most potent resulting compound (5) inhibited hIcmt in vitro with low micromolar potency (IC50 = 1.5 ± 0.2 μM) and was kinetically characterized as a competitive inhibitor for prenylated substrates and a non-competitive inhibitor for the cofactor and methyl donor S-adenosylmethionine (SAM). These inhibitors offer important structure activity relationships for the future development of hIcmt inhibitors with in vivo activity.

INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE

Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

The present applicationpresent application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.